E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pulmonary Arterial Hypertension |
Ipertensione Polmonare Arteriosa |
|
E.1.1.1 | Medical condition in easily understood language |
Pulmonary arterial hypertension is an increase in blood pressure in the pulmonary arteries leading to shortness of breath, dizziness, fainting and other symptoms. |
L`ipertensione arteriosa polmonare consiste in un aumento della pressione sanguigna nelle arterie polmonari che determina sintomi quali fiato corto, capogiri, stanchezza ed altri. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10064911 |
E.1.2 | Term | Pulmonary arterial hypertension |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the long-term safety and tolerability of ACT-293987 in patients with pulmonary arterial hypertension (PAH). |
Valutare a lungo termine la sicurezza e tollerabilita' di ACT-293987 nei pazienti con Ipertensione Arteriosa Polmonare (PAH) |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Signed informed consent prior to initiation of any study-mandated procedure. - Patients who have completed the double-blind study AC-065A302 as scheduled per protocol (i.e., treated until unblinding of the study), or who have experienced a clinical worsening of PAH (adjudicated by the CEC) during study AC-065A302. - Women of child-bearing potential included in study AC-065A303 must use a reliable method of contraception (with a failure rate of less than 1% per year) until one month after study drug discontinuation. |
- Consenso informato firmato prima di iniziare qualsiasi procedura prevista dallo studio - Pazienti che hanno completato lo studio in doppio cieco AC-065A302 come da protocollo (cioe`, trattati fino all`apertura del cieco dello studio) oppure che hanno avuto un peggioramento clinico dellâÂÂIpertensione Arteriosa Polmonare (aggiudicato dal Comitato per gli Eventi Critici (Critical Event Committee, CEC)) nello studio AC-065A302 - Donne in eta` fertile1 incluse nello studio AC-065A303 devono fare uso di un metodo contraccettivo affidabile (con un tasso di fallimento annuo inferiore allâÂÂ1%) fino ad un mese dopo lâÂÂinterruzione del trattamento con il farmaco in studio |
|
E.4 | Principal exclusion criteria |
- Any major violation of protocol AC-065A302. - Females who plan to become pregnant during the study, or are breastfeeding. - Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence, or psychiatric disease. - Known hypersensitivity to ACT-293987 or any of the excipients. |
- Pazienti con qualsiasi violazione importante al protocollo AC-065A302 - Donne che hanno intenzione di programmare una gravidanza nel corso dello studio, oppure sono in allattamento - Pazienti con qualsiasi fattore o patologia conosciuto/a, che potrebbe interferire con il conformarsi al trattamento, la conduzione dello studio o lâÂÂinterpretazione dei risultati, come ad esempio dipendenza da droghe o alcool, o disturbi psichici - Pazienti con ipersensibilita` nota a ACT-293987 o ad uno qualsiasi degli eccipienti |
|
E.5 End points |
E.5.1 | Primary end point(s) |
No primary efficacy endpoint is considered for this OL study. The primary endpoint for this study is safety and tolerability. |
Nessun endpoint primario di efficacia viene considerato per questo studio, il cui endpoint primario e' la sicurezza e la tollerabilita'. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After Visit 5, safety will be assessed every 6 months |
Dopo la Visita 5, la sicurezza sara' valutata ogni 6 mesi |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability |
Tollerabilita' |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 60 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Belarus |
Canada |
Chile |
China |
India |
Israel |
Korea, Republic of |
Malaysia |
Mexico |
Peru |
Russian Federation |
Singapore |
Switzerland |
Taiwan |
Thailand |
Turkey |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Study treatment for each patient lasts from his/her Visit 1 date until the end of the trial i.e., until whichever of the following occurs first: (i) the approval of ACT-293987 in this indication is obtained in the patient`s country, (ii) the sponsor decides to stop study AC- 065A303/GRIPHON OL, or (iii) the patient, or the investigator decide to discontinue study drug. |
Il trattamento dura da V1 a Fine Studio, a seconda di quale dei seguenti casi avviene prima: 1.Approvazione di ACT-293987 per l`indicazione nel paese del paziente; 2.Sponsor interrompe studio; 3. paziente o PI interrompere trattamento in studio |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |